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ACETYLSALICYLIC ACID FOR CARDIOVASCULAR PREVENTION
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OBJECTIVES: Low-dose acetylsalicylic acid (ASA; 75–325 mg daily) is a mainstay of 
cardiovascular (CV) prevention. However, some patients taking low-dose ASA may 
experience upper gastrointestinal (GI) symptoms that are associated with poor adher-
ence to and discontinuation of low-dose ASA. Established gastroprotective strategies, 
e.g. concomitant proton pump inhibitor (PPI) therapy, may ameliorate these symptoms 
and thus improve low-dose ASA adherence. METHODS: This subanalysis of a mul-
tinational, observational, non-interventional study (NCT00681759) conducted in the 
United States, Canada and France assessed PPI prescription rates (one-time retrospec-
tive survey) and daily PPI adherence rates (prospective 3-month eDiary phase) in adult 
patients with increased GI risk who had been prescribed low-dose ASA for manage-
ment of CV risk. Here, increased GI risk was deﬁ ned as a history of peptic ulcer and/
or complications or additional antiplatelet use (clopidogrel, ticlopidine, dipyridamole). 
RESULTS: A total of 195 of the 1770 patients in the survey were identiﬁ ed as having 
increased GI risk (history of peptic ulcer and/or complications, n = 109; concomitant 
antiplatelet therapy, n = 74; both factors, n = 12); 119 (61%) of whom were not 
prescribed a PPI. a total of 340 patients entered the eDiary phase, of whom 110 were 
prescribed a PPI before the ﬁ rst diary day; of these, 79 patients were prescribed a daily 
PPI for the 3-months. Among these patients, fewer than half (n = 37) took >75% of 
prescribed daily PPIs. Almost one-third (n = 25) did not take their prescribed daily 
PPI at all during the 3-month phase. CONCLUSIONS: PPI prescription and adherence 
rates are low among patients with increased GI risk receiving low-dose ASA for CV 
risk management. Strategies that deliver gastroprotection with improved adherence 
rates during low-dose ASA therapy in patients with increased GI risk may be 
warranted.
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MEDICATION ADHERENCE AND PERSISTENCE IN THE TREATMENT OF 
ULCERATIVE COLITIS: ANALYSES WITH THE RAMQ DATABASE
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OBJECTIVES: Non-adherence with oral mesalazines has a signiﬁ cant impact on treat-
ment outcome which is one of the most important predictors for relapse in ulcerative 
colitis. The objective of this study was to assess adherence and persistence with oral 
mesalazines, particularly to analyze whether adherence with oral mesalazines is linked 
to the use of once daily high strength Mezavant® compared to more frequent dosing 
and/or low strength oral mesalazines. METHODS: A retrospective prescription claims 
analysis of a random sample of patients from the Quebec provincial public health plan 
(RAMQ) database was conducted. New users of a mesalazine formulation during the 
period from January 2005 to December 2009 and with no diagnosis of Crohn’s disease 
were eligible for inclusion in the analysis. Treatment adherence was estimated using 
medication possession ratio over a one-year period. For the analysis of persistence to 
treatment, patients were considered non-persistent if they had not used the mesalazines 
medication for a period of twice the median duration of prescriptions. Proportion of 
patients who were persistent was estimated at 3-, 6-, and 12 months after index 
prescription. RESULTS: The mean age of the study sample was 55.7 years (SD = 18.2) 
and the proportion of males and female were similar (48.8% vs. 51.2%). The prop-
ortion of patients ≥80% compliant on the mesalazine long acting formulation 
(Mezavant®) (46.3%) was signiﬁ cantly higher compared with all other mesalazine 
formulations (1.6% to 26.0%) (P < 0.001). The proportion of patients who were 
persistent at 12 months on Mezavant® (70.2%) was higher when compared with those 
on any other mesalazine formulations (14.5% to 42.6%) (P < 0.001). Similar trends 
were observed at all time points examined. CONCLUSIONS: Results of these prescrip-
tion claims analyses indicate that adherence and persistence to mesalazine formula-
tions are relatively poor, however improved adherence and persistence are observed 
with the long acting formulation (Mezavant®).
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OBJECTIVES: The effectiveness of 5-aminosalicylic acid (5-ASA) therapy for mild to 
moderate ulcerative colitis (UC) is commonly affected by poor medication adherence. 
The present study was designed to determine if adherence behaviour could be 
explained by differences in patient preferences for 5-ASA therapies. METHODS: A 
discrete choice experiment (DCE) survey was used to explore patient preferences for 
different aspects of oral 5-ASA therapy. The DCE survey captured trade-offs that 
patients were willing to make and was based on a literature review, clinician inter-
views, and in-depth interviews with UC patients (followed by cognitive debrieﬁ ng). 
Six attributes were identiﬁ ed: Ease–of–swallowing, Number of administrations per 
day, Number of pills (per administration), Symptom ﬂ are resolution; Likelihood of 
ﬂ are occurrence and Cost (to estimate willingness-to-pay (WTP) for improvements in 
attributes). Adherence behaviour was assessed using the Modiﬁ ed Morisky Scale. 
Participants (mild to moderate UC patients, n = 400) in the UK, US, Germany, and 
Canada were recruited through specialist patient recruitment agencies and the survey 
was administered via the internet, following IRB approval. Data were analyzed using 
the conditional logit procedure. RESULTS: Clinical effectiveness was most highly 
valued by participants independent of country of origin (e.g. reduction in annual ﬂ are 
risk to 10%: WTP = £78.81 per month) and a return to normal bowel functioning 
with mucosal healing (WTP = £29.24). Signiﬁ cant interaction terms identiﬁ ed that 
people who reported good adherence placed greater value on symptom control com-
pared with self reported poor adherers to therapy (P = 0.011). CONCLUSIONS: Data 
suggest that the most highly valued aspect of therapy was effectiveness. Therefore, 
patients may adhere to a medication better if they place greater value on its ability to 
effectively treat their UC. Furthermore, these data suggest a possible avenue for physi-
cians to explore with their patients to improve adherence to the treatment regimen by 
highlighting the risk-beneﬁ t proﬁ le of 5-ASAs in the treatment of UC.
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OBJECTIVES: The clinical trial programme for Prucalopride, a selective and high 
afﬁ nity 5-HT4 receptor agonist, incorporated a constipation speciﬁ c HRQoL measure 
(PAC-QOL) and SF-36 but not EQ-5D. a mapping relationship was developed to link 
EQ-5D to PAC-QOL using established algorithms linking EQ-5D and SF-36. 
METHODS: Trial responses (n = 5488) on a common patient data set enabled an 
empirical link to be established between the SF-36 and PAC-QOL which was extended 
to EQ-5D through the established algorithm. Having established this relationship a 
range of functional forms for mapping PAC-QOL onto EQ-5D were tested ranging 
from a simple linear relationship to more complex mapping structures incorporating 
quadratic and interactive terms. RESULTS: The relationship between PAC-QOL and 
EQ-5D was generally good. The estimated equation for deriving EQ-5D from 
PAC-QOL in its’ simplest linear functional form was: EQ-5D = 97.7–9.8 (PAC-QOL). 
This implies that a one point change in PAC-QOL overall score would lead to a 9.8% 
change in EQ-5D. As expected, the mapping was largely limited to the upper health 
states of EQ-5D given that chronic constipation by itself is unlikely to lead to the 
severest forms of disability. This initial regression analysis displayed elements of non-
linearity and hence a more complex analysis was undertaken which incorporated 
square and interaction terms. This new functional form facilitated a more accurate 
relationship to be established between PAC-QOL and EQ-5D. CONCLUSIONS: 
Mapping is required whenever a preference based generic HRQoL measure is not 
directly collected in clinical trials. Very limited theoretical guidance is available to 
structure such analyses and therefore empiricism largely rules. However by testing the 
robustness of the results to different assumptions and functional forms a robust 
mapping can be developed. This process was employed here to convert PAC-QOL 
into EQ-5D utility scores for incorporation into Cost Utility analyses.
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IDENTIFYING ENDPOINTS FOR IRRITABLE BOWEL SYNDROME (IBS) 
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OBJECTIVES: 1) Identify a comprehensive set of symptoms experienced by patients 
with irritable bowel syndrome with constipation (IBS-C), and 2) Identify the most 
important symptoms for measurement in clinical trials for IBS-C. METHODS: Two 
iterative sets of in-depth interviews were conducted in different US cities, with a total 
of 27 participants meeting modiﬁ ed Rome II criteria for IBS-C. a semi-structured 
interview guide was used, beginning with a series of open-ended questions to elicit all 
relevant symptoms, followed by interviewer probes to fully understand the relation-
ships among the concepts. Multiple rating and ranking methods were used to develop 
a subset of IBS-C symptoms of greatest importance to patients. For example, partici-
pants were asked to identify their most bothersome IBS-C symptoms, as well as those 
in which they would most like to see an improvement with treatment. RESULTS: 
When asked to describe their IBS-C symptoms, patients reported 54 potentially distinct 
concepts: 8 abdominal symptoms, 12 bowel symptoms, 31 additional physical symp-
toms (e.g., nausea, headache), and 3 emotional issues (e.g., irritability, depression). 
Some symptom terms were highly related (e.g., abdominal pain and stomach ache) 
and others could be considered consequential to IBS-C (e.g., hemorrhoids, vomiting). 
Results of the subsequent rating and ranking tasks suggest that abdominal pain, 
abdominal discomfort, bloating, stool frequency, stool consistency, straining, and 
incomplete evacuation were distinct and represent patients’ most bothersome symp-
toms. Further, according to the patients, improvements in these symptoms would 
constitute an improvement in IBS-C overall. CONCLUSIONS: Patient input is vital 
to identify the full spectrum of symptoms and to determine an optimal set of clinical 
trial endpoints. Within and across the two separate rounds of interviews, participants 
consistently reported the importance of abdominal pain, abdominal discomfort, bloat-
ing, stool frequency, stool consistency, straining, and incomplete evacuation, demon-
strating concept saturation and supporting the measurement of these symptoms in 
IBS-C clinical trials.
